IRCT20151123025202N52 IRCT 2026-03-09 Hamedan University of Medical Sciences Omalizumab in Polyp Recurrence Prevention Study of the effect of omalizumab on the recurrence of polyposis in patients with allergic fungal sinusitis who underwent surgery 2026-03-21 anticipated 36 Recruiting https://irct.ir/trial/89274 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Block randomization with 4-patient blocks, Blinding description: Outcome assessor and data analyst are blinded to group allocation. 2-3 Allergic fungal sinusitis. Intervention 1: Intervention group: In addition to the standard routine treatment regimen (serum lavage, mucolytics, and topical corticosteroids), omalizumab treatment was initiated at a dose of 0.016 mg/kg per injection based on the existing protocol and continued for 2 months. Intervention 2: Control group: They will receive only the standard routine treatment regimen (serum lavage, mucolytics, and topical corticosteroids) and placebo (injectable vitamins B1 and B6 (B complex). Yes - There is a plan to make this available What will be shared: All data can be shared except for authors names When: From 2027 onwards it is permissible To whom: Clinical professionals and Researchers in all fields Conditions: For treatment and develop research and science Where to obtain: Correspond to the email address of the scientific responsible for the study How to obtain: Send and receive email Comments: